Health

Results: 481-492 of 6055

NuCana Reports First Quarter 2025 Financial Results and Provides Business Update

PR Newswire associated0

Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

PR Newswire associated0

Full Dose-Escalation Data Show Continued High Response Rates and Favorable Safety Profile of ISB 2001, a First-in-Class BCMA × CD38 × CD3 Trispecific Antibody, for the Treatment of Relapsed/Refractory Multiple Myeloma

STEMCELL Technologies, Canada’s largest biotechnology company, is pleased to announce the acquisition of Cellular Highways Ltd from TTP Group Ltd. Cellular Highways is a biotechnology company based near Cambridge, United Kingdom, that specializes in advanced cell sorting technologies with applications in cell and gene therapy, drug discovery, and general cell research, especially where cells are fragile. The acquisition includes the revolutionary Highway1 instrument, which uses Cellular Highways’ proprietary VACS™ (Vortex-Actuated Cell Sorting) technology. Highway1 enables researchers and cell therapy developers to process cells more efficiently while maintaining high cell integrity for sensitive applications in research and therapeutic development. This significantly reduces the timelines and costs for research and development.

STEMCELL Technologies Announces Acquisition of Cellular Highways

Corcept Presents Pivotal Clinical Data in ASCO Late-Breaker with Simultaneous Publication in The Lancet: Relacorilant Improves Progression-Free and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer

Vantive to Invest More Than $1 Billion in Advancing Kidney Care and Vital Organ Support Through Digitally-Enabled Therapies

Orexo to present clinical data for OX640 at the EAACI Congress

iFIT Expands Global Reach with Rollout of AI Coach in 19 Countries

PR Newswire associated0

Phenomenex Launches Cutting-Edge 0.15 mm ID Micro LC Columns and Traps for Precision Low-Flow Applications

PR Newswire associated0

Endo Champions Men's Health Month with Education, Awareness, and Outreach

ImmunAbs Announces FDA Phase 2 IND Approval of IM-101, a Novel Complement C5 Inhibitor, for Treatment of Myasthenia Gravis

PR Newswire associated0

Alkermes Highlights Data From Psychiatry Portfolio at Spring 2025 Scientific Conferences